News from SGC

Posted on Friday 9th of August 2013
Today we learned the sad news that Tony Pawson, a former member of the SGC Scientific Committee, and a friend and colleague of many SGC scientists, died this week. He was a fantastic person, scientist and collaborator.
Posted on Tuesday 16th of July 2013
The Structural Genomics Consortium (SGC) recently launched a new scientific public-private partnership in tuberculosis and malaria drug discovery: the Structure-guided Drug Discovery Coalition, SDDC.
Posted on Tuesday 7th of May 2013
Boehringer Ingelheim announced that it has joined the Structural Genomics Consortium (SGC) for further research into incurable diseases.
Posted on Friday 3rd of May 2013
UK Prime Minister David Cameron, visits SGC Oxford and discusses open access drug discovery with Chief Scientist Chas Bountra.
Posted on Tuesday 2nd of April 2013
A group led by Dr. Liz Carpenter at the Structural Genomics Consortium have now mapped all the atoms that build ZMPSTE24 using a technique called X-ray crystallography and found a completely novel fold – the way in which the atoms in the enzyme are sequentially arranged.
Posted on Friday 16th of November 2012
GlaxoSmithKline has developed a potent, selective, cell-active EZH2 inhibitor, GSK343, and has made this available as a chemical probe as part of the SGC epigenetics initiative.
Posted on Wednesday 19th of September 2012
The Pfizer-SGC project aims to tackle a rare, hereditary metabolic disorder called homocystinuria, which leaves patients unable to metabolise the amino acid methionine.
Posted on Tuesday 31st of July 2012
Researchers from Oxford University, GlaxoSmithKline, Cellzome, and Memorial Sloan Kettering Hospital have developed and characterised the first selective inhibitor for a specific class of histone demethylases
Posted on Thursday 19th of July 2012
Life Technologies Corporation (NASDAQ: LIFE) today announced it has signed a collaborative partnership with the Structural Genomics Consortium (SGC), and several groups of leading expert scientists in antibody technology at the Universities of Chicago and Toronto, to generate a first-ever master set of quality epigenetic recombinant antibodies for use in disease-related research.
Posted on Friday 1st of June 2012
TORONTO, June 4, 2012 – The Structural Genomics Consortium (SGC), a group of expert researchers in recombinant antibody technology from the Universities of Toronto and Chicago and an industry partner have entered into a pioneering public-private partnership to generate renewable recombinant antibodies for epigenetic targets.

Pages

Subscribe to News from SGC
glqxz9283 sfy39587stf02 mnesdcuix8
sfy39587stf03